Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
OncoCell MDx
AddedFeb 15, 2024
UpdatedJun 18, 2026
OncoCell MDx

OncoCell MDx

Series B

OncoCellMDx: A Corvallis-based medical firm innovating noninvasive diagnostic tests for cancer severity.

HQ
Corvallis, OR, US
Founded
2012
Overview
Compare
Fundraising
Employees

OncoCell MDx is a medical organization based in Corvallis, Oregon, focused on developing and commercializing novel diagnostic tests using proprietary technologies from Harvard Medical School. Their primary product is a noninvasive blood-based immunogenomic assay designed to assess the severity of prostate cancer. The company also has a pipeline that includes other oncology and non-oncology indications.

OncoCell MDx has made significant strides in the medical diagnostics field, particularly with their innovative approach to noninvasive testing. Their technology aims to provide physicians with deeper insights into underlying pathologies, enhancing patient care. The company's impact is marked by its advanced diagnostic solutions that promise to improve disease management and patient outcomes.

OncoCell MDx - Similar Companies

OnCirc Diagnostics logo

OnCirc Diagnostics

Accelevir Diagnostics logo

Accelevir Diagnostics

SynapDx logo

SynapDx

PrognosDx Health logo

PrognosDx Health

BioMarker Strategies logo

BioMarker Strategies

Predictive Biosciences logo

Predictive Biosciences

CancerMark logo

CancerMark

Evincis Bio logo

Evincis Bio

Foresight Diagnostics logo

Foresight Diagnostics

foresight-dx.com

Aeena Dx logo

Aeena Dx

Cicero Diagnostics logo

Cicero Diagnostics

CytoTest logo

CytoTest

Oncocyte logo

Oncocyte

oncocyte.com

OncoHealth logo

OncoHealth

oncohealthcorp.com

AgenDx Biosciences logo

AgenDx Biosciences

OncoCell MDx - Quick Facts

Who are OncoCell MDx's competitors?

Companies similar to OncoCell MDx include OnCirc Diagnostics, Accelevir Diagnostics, SynapDx and PrognosDx Health.

When was OncoCell MDx founded?

OncoCell MDx was founded in 2012.

Where is OncoCell MDx's headquarters located?

OncoCell MDx's headquarters is located in Corvallis, OR, US.

When was OncoCell MDx's last funding round?

OncoCell MDx's most recent funding round was for $22.2M (USD) in September 2019.

How much has OncoCell MDx raised to-date?

As of Sep 11, 2019, OncoCell MDx has raised a total of $22.2M (USD).

How many employees does OncoCell MDx have?

OncoCell MDx has 30 employees as of Feb 4, 2024.

OncoCell MDx - Classification

Ownership
  • Private
Technology
  • Analytics
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Diagnostic Tests
Tags
  • Data Information
  • Healthcare
  • Healthtech
NAICS
  • 621000Ambulatory Health Care Services
  • 621500Medical and Diagnostic Laboratories
  • 621510Medical and Diagnostic Laboratories
  • 621511Medical Laboratories
  • 620000Health Care and Social Assistance
SIC
  • 8070Medical And Dental Laboratories
  • 8071Medical Laboratories
  • 8000Health Services
Show 2 more industry codes
SIC
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified